2143 results about "Cryopreservation" patented technology

The invention relates to cells or tissues having an increased amount of regulatory proteins, including cytokines, growth factors, angiogenic factors and / or stress proteins, and methods of producing and using those cells or tissues. The invention is based on the discovery that the production of regulatory proteins is induced in cells or tissue constructs following cryopreservation and subsequent thawing of the cells or constructs. The compositions and methods of this invention are useful for the treatment of wound healing and the repair and / or regeneration of other tissue defects including those of skin, cartilage, bone, and vascular tissue as well as for enhancing the culture and / or differentiation of cells and tissues in vitro.

The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are methods of efficiently isolating RPE cells from cultures containing heterogeneous cell types, allowing for substantially pure RPE cell cultures to be established. Additionally, novel methods for the cryopreservation of RPE cells are provided.

A mold is disclosed for forming a freezable and thawable bag of uniform thickness, especially useful for cryopreservation of thermolabile substances. The mold features one or more recessed planar surfaces, including radiused peripheral walls about the recesses, a planar top surface, and means for conforming a blank sheet to the mold. Two mold halves combine to form a completed bag. The mold halves may be complimentary.

The present invention relates to a composition for implantation in the subretinal space of an eye, the composition including amniotic membrane, which may be cryopreserved human amniotic membrane, and a plurality of retinal pigment epithelial (RPE) cells or RPE equivalent cells present at the amniotic membrane. The amniotic membrane may be intact, epithelially denuded, or otherwise treated. The invention includes the use of amniotic membrane for the culturing of RPE cells thereon, forming a surgical graft for replacement of Bruch's membrane as a substrate, and for the transplanting of RPE cells to the subretinal space. The composition does not elicit immunological reactions to alloantigens or to RPE specific autoantigens; and exerts anti-inflammatory, anti angiogentic, and anti-scarring effects. The invention includes methods and kits for making or using composites including amniotic membrane and RPE cells. Also disclosed is a device for harvesting RPE cells.

A bag, method of manufacture and process are disclosed for the cryopreservation of thermolabile substances. The bag is characterized as having substantially uniform thickness throughout its length and height. The bag features a radiused peripheral edge wall for stress relief and to provide the constant cross-section. A peripheral flashing circumscribes the radiused edge wall and provides a suitable purchase area for sealing so that the thus formed bag is less susceptible to fracture particularly when exposed to cryogenic temperatures. The uniform thickness of the bag promulgates uniform heat transfer to and from the contents of the bag in relation to any surrounding medium at a different temperature. The bag affords more space for efficient storage and reduces heat invasion into the contents of the bag when a plurality of bags are placed with their larger planar surfaces in contact with each other.

Disclosed are compositions for mammalian, avian or piscian reproductive cells and methods for the collection, holding, processing, in vitro fertilization, sexing culturing, or storing (including long-term cryopreservation) of mammalian, avian, or piscian reproductive sperm cells. The compositions comprise a suitable reproductive cell media and a transforming growth factor, an insulin-like growth factor, or zinc, and, optionally, inositol, transferrin, or fructose, or combinations thereof.

Cryopreserved boar spermatozoa is much less fertile than that of other species, which could be due to damage to sperm membrane lipids during the cryopreservation process. Incorporation of selected lipids improves the survival of boar spermatozoa following cryopreservation.Liposomes were made from lipids extracted from head plasma membrane (HPM) of boar spematozoa or from selected lipids (SL) which contained specific phospholipids. At a fixed lipid concentration, fusion efficiency with spermatozoa as measured by flow cytometry and R18 dequenching was affected by lipid type, sperm concentration and incubation time.SL and HPM improved sperm viability (SYBR-14 and propidium iodide) and motility during cooling to 5C., with SL±egg yolk better than or equal to HPM (P<0.05). Post-thaw, egg yolk showed a strong cryoprotective effect. Compared to HPM, SL-treated sperm had higher post-thaw viability, progressive motility and total motility in the extender including egg yolk and higher viability in the extender excluding egg yolk (P<0.05).

A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic / metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.

A disclosure is made of various apparatus and methods for culturing and preserving cells and tissue in ways that minimize contamination potential, direct cells to reside in desired areas, allow uniform cell distribution during seeding, provide optimal growth conditions by controlling the amount of medium residing in proximity of cells, allow desired compounds and molecules to reside in proximity of the cells, allow co-culture, provide for efficient scale up, allow a desired shape of tissue to be created while retaining a closed system, and allow cryopreservation and reconstitution of cell and tissue while retaining a closed system. The apparatus and methods can be combined to prevent the need to remove the tissue from the enclosure at any point during the sterilization, seeding, culturing, cryopreservation, shipping, or restoration process. Also disclosed is an apparatus and method of pipette interface with a container in a manner that blocks contaminants from entering the container.

A method of preserving, storing and transplanting mammalian donor organs. The method includes the cooling of refrigeration preservation, loading pre-freezer preservation, cryopreservation and washing solutions at least containing polyvinylpyrrolidone, a calcium channel blocker, a nucleoside, potassium chloride, polyethylene glycol, at least one amino acid, and a steroid to a temperature of 2° to 4° C. and / or of 0° to 2° C., harvesting a donor organ, perfusing it with one or more of the solution, immersing it in one or more of the solutions and storing it at a temperature above 0° C. or at a temperatures below 0° C. The cryopreservation solution also contains cryopreservative agents. Preserved organs may be transplanted directly from refrigeration storage or from freezer storage by cooling the washing refrigeration preservation solutions to 2° to 4° C., perfusing the organ with washing solution and then preservation solution, and transplanting it.

The present invention relates to the use of polysulfated polysaccharides in combination with progenitor cells to improve the viability of the progenitor cells including improving the cryopreservation of the progenitor cells and provides novel compositions, methods and uses. The present invention also relates to the use of polysulfated polysaccharides to regulate the proliferation and differentiation of progenitor cells.

The invention discloses a biodegradable particle-cell composition having at least one biodegradable particle, at least one receptive group covalently linked thereto, and a cell anchored thereto. The particle can be polylactide, a polylactide-lysine copolymer, polylactide-lysine-polyethylene glycol copolymer, starch, or collagen. The receptive group can be an antibody, a fragment of an antibody, an avidin, a streptavidin, or a biotin moiety. Moreover, the particle can also have extracellular matrix components other than collagen. The particle-cell compositions can be used for selection of cells from a population, for cell culture of anchorage-dependent cells, for cryopreservation of anchorage-dependent cells, and for transplantation as a cell therapy.

The invention discloses a chiffon cake pre-blend flour requiring no egg separation, a chiffon cake adopting the pre-blend flour, and a preparation method of the chiffon cake. The chiffon cake pre-blend flour comprises the following components by weight percentage: 45% to 50% cane sugar, 40% to 45% self-raising flour, 6% to 8% albumen powder, 2% to 3% modified starch, 0.4% to 0.8% edible gum, 0.2% to 0.4% salt, 0.1% to 0.3% acidity regulator and 0.1% to 0.3% food flavor. The chiffon cake prepared by the chiffon cake pre-blend flour is characterized in that compared with traditional preparation technology, egg separation leavening is not required and tartar powder is not needed also. The preparation method of the chiffon cake is simplified, and the prepared chiffon cake is soft, moisture-contained and flexible, and is cryopreservation resistant, and the quality of the cake is improved compared with that adopting traditional preparation method.

The invention discloses a liquid nitrogen container and a cryogenic vial pick-and-place device. The liquid nitrogen container comprises a container body, and further comprises a rotary disc, a cryopreservation frame, a central shaft and a driving assembly, wherein an opening is formed in the container body; the rotary disc is arranged in the container body; the cryopreservation frame is supported by the rotary disc and comprises a plurality of layers of placement faces; the included angle between each placement face layer and the rotary disc is 40-60 degrees; the central shaft is perpendicularly arranged with and fixedly connected with the rotary disc; the driving assembly is electrically connected with the central shaft and used for driving the central shaft to rotate; and the central shaft is used for driving the cryopreservation frame to rotate through the rotary disc to reach the opening of the container body. By adoption of the liquid nitrogen container and the cryogenic vial pick-and-place device, the workload of operating personnel is reduced, the error rate of manual picking of cryogenic vials is lowered, and the potential safety hazard for the operating personnel is avoided. The liquid nitrogen container and the cryogenic vial pick-and-place device are particularly suitable for the work of picking cryogenic vials in a high-capacity biological sample bank, and meet the technical requirement for storage in the high-capacity biological sample bank.

An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed. The use of the plasma-like solution in organ transplant, novel chemotherapy procedures, and tissue, organ and organism cryopreservation are also disclosed.

This invention is a storage device (cryocontainer) for the vitrification method of cryopreservation that uses shape memory materials to create a novel shape-shifting feature in which the relevant heat transfer zone of the cryocontainer can be thermally morphed between a shape conducive to biological specimen handling and to a shape conducive to rapid heat transfer. This feature utilizes the temperature induced phase transformation of shape memory materials. The temperature inducement occurs naturally within the normal temperature changes that occur during vitrification.

Gel-based medium compositions and a method of use thereof in normothermic, hypothermic or cryopreservative storage and transport of cell samples are described. These gel-based compositions preferably include an agent that inhibits apoptosis, together with a gelling agent. Such gel-based medium compositions protect various cell samples, such as animal or plant organs, tissues and cells, from the mechanical, physiological and biochemical stresses inherently associated with liquid preservation techniques.

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

Methods, processes and systems for procuring, isolating and cryopreserving fetal placental cells are provided. A population of fetal placental cells is also provided.

The invention relates to a method for cultivating autologous umbilical cord mesenchymal stem cells by adopting human umbilical cord blood rich platelet lysate. The conventional cell bank preparing processes adopt blood serum of calves or fetal calves to cultivate, digest, cryopreserve and the like, so that the risk of heterogeneous protein residue certainly exists in the application of clinic umbilical cord stem cells in the future. The method comprises the following steps of umbilical cord blood rich platelet serum preparation, platelet lysate preparation, preparation of serous without platelet, the confirmation of the content of cell factors, namely PDGF-AB, FGF2, TGF-Beta and VFGF in the platelet lysate, the separation and the primary culture of umbilical cord stem cells, the culture and passage of umbilical cord stem cells, the cryopreservation of umbilical cord stem cells, and the karyotype analysis. The method is used for cultivating stem cells.

The invention provides a cryopreservation method and a resuscitation method of neural stem cells (NSCs), and provides a cryopreserved NSC solution and a resuscitated NSC solution with cell survival rates higher than 90%. The solutions are prepared with the methods provided by the invention. Also, the invention provides a cryopreservation medium and a resuscitation medium used in the NSC cryopreservation method and resuscitation method.

The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. A composition of the invention comprises an oral delivery vehicle comprising an oxalate degrading bacteria, one or more cryopreserving agents and one or more excipients. A composition of the invention is enteric coated and has a suitable shelf-life and acceptable properties to avoid negative impact from gastric fluid when it is orally administered.

Method for preserving tissue including immersing the tissue in a solution having a cryoprotectant concentration of at least 75% by weight, a cooling step where the tissue is cooled to a temperature between the glass transition temperature of the solution having a cryoprotectant concentration of at least 75% by weight and −20° C., a storage step where the tissue is stored at a temperature between the glass transition temperature of the solution and −20° C., a rewarming step, where the tissue is warmed, and a washing step.

A cryopreservation solution of tissue engineering products uses DMEM culture solution as a basic solvent which is added with vitamin B, vitamin C, chondroitin sulfate, beta-integrin, cromolyn sodium, cytochalasin B, L-glutamine, bovine serum albumin, fetal bovine serum, trehalose, sodium carbonate, polysucrose-70, and dimethyl sulfoxide added during freezing storage. The cryopreservation solution provided by the invention has little toxicity to cells and long storage time, and can be stored for six months under 80 DEG C below zero, and 12 to 18 months in liquid nitrogen; and the cell viability of the resuscitated cells can be over 60%. The stored tissues can be simply and conveniently used after being resuscitated for only three to five min in water bath under the temperature of 37 DEG C and being washed by sterilized saline water. The invention can be widely used, and is suitable for tissue engineering skin, tissue engineering cornea, tissue engineering blood vessel, tissue engineering nerve and the like, and also is applicable to the cryopreservation of normal tissues.

The invention relates to the field of cell culture, in particular to cell cryopreservation liquid, application thereof and a cryopreservation method of megakaryocyte progenitor cells. The cell cryopreservation liquid comprises DMSO, fetal calf serum, dextran, trehalose and albumin. By means of the cell cryopreservation liquid, the cytoactive of the megakaryocyte progenitor cells can be well maintained during the cryopreservation period, and damage to cells in the cryopreservation and resuscitation processes is lowered. According to the cell cryopreservation liquid, application thereof and the cryopreservation method of the megakaryocyte progenitor cells, the cryopreservation and temperature reduction processes are softer, the cells are stored in liquid nitrogen after the temperature reduction process is conducted, the influence on the cytoactive is small, and damage to the cells in the cryopreservation process is lowered. It is indicated by experiments that the vigour of the resuscitated cells can reach 94% one month after the megakaryocyte progenitor cells are cryopreservated in the cryopreservation liquid, and multiplication activity is good, and the cell cryopreservation liquid is significantly superior to the prior art.

The invention discloses a cell cryopreservation fluid which can be used for performing cryopreservation on mesenchymal stem cells or other cells. The cell cryopreservation fluid is prepared from the following ingredients: PBS or normal saline or a basal culture medium serving as a main ingredient, as well as one or more of polyethylene glycol, propanediol, Ectoin, albumin, trehalose, proline and poloxamer 188 which serve as additive ingredients. The cell cryopreservation fluid disclosed by the invention does not contain serums and DMSO, have the definite additive ingredients, and is controllable in quality, high in batch stability and high in safety. By virtue of preserving cells with the cell cryopreservation fluid, revived cells are high in survival rate, and the cellular morphology, the multiplication capacity and the differentiation potential are not influenced; the cell cryopreservation fluid can be used for replacing cryopreservation fluids containing the serums and the DMSO.

A cryopreservation vessel of the present invention includes a vessel body which holds a low-temperature liquefied gas, a cap which closes an opening section of the vessel body and has a plurality of through holes that are formed so as to pass through in a vertical direction, and ampoule storing tools which are housed so as to be able to pass through the through holes of the cap, and the ampoule storing tools are each comprised of a support pillar and a plurality of ampoule storing sections which are equipped with the support pillar so as to be arrayed in a vertical direction of the support pillar.